DOA
LSTA icon

D'Orazio & Associates’s Lisata Therapeutics LSTA Stock Holding History

D'Orazio & Associates’s Portfolio LSTA Stock Details LSTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-17
Closed -$1K – 282
2016
Q3 		$1K Hold
17
– – ﹤0.01% 271
2016
Q2 		$1K Hold
17
– – ﹤0.01% 283
2016
Q1 		$1K Buy
+17
New +$1.67K ﹤0.01% 281

Other funds holding LSTA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

D'Orazio & Associates's LSTA Position: Q4 2016 in Review

D'Orazio & Associates sold out of Lisata Therapeutics (LSTA) in Q4 2016, closing a stake of 17 shares — an estimated $1K sold.

D'Orazio & Associates first reported a position in LSTA in Q1 2016 and held it in 3 quarters. The position peaked at $1K in Q3 2016. 30 funds tracked by Wall St. Rank hold LSTA as of Q4 2016.

  • D'Orazio & Associates reported no remaining Lisata Therapeutics position as of Q4 2016 after selling out during the quarter.
  • D'Orazio & Associates sold 17 Lisata Therapeutics shares in Q4 2016, an estimated $1K.
  • D'Orazio & Associates first reported a position in Lisata Therapeutics in Q1 2016 and held it in 3 quarters.
  • D'Orazio & Associates's Lisata Therapeutics position peaked at $1K in Q3 2016.
  • 30 funds tracked by Wall St. Rank held Lisata Therapeutics as of Q4 2016.

Based on D'Orazio & Associates's 13F filing for Q4 2016, filed 15 Feb 2017.